Research Article

The Class III PI3K/Beclin-1 Autophagic Pathway Participates in the mmLDL-Induced Upregulation of ET\textsubscript{A} Receptor in Mouse Mesenteric Arteries

Xi Xie,\textsuperscript{1} Chen Chen,\textsuperscript{1} Cang-Bao Xu\textsuperscript{2}, Jie Lin,\textsuperscript{1} Lei Cao\textsuperscript{3}, Gen Chen,\textsuperscript{1} and Jie Li\textsuperscript{1}\textsuperscript{1}

\textsuperscript{1}The First People’s Hospital of Chenzhou, Institute of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan, China
\textsuperscript{2}Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China
\textsuperscript{3}Department of Pharmacology, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China

Correspondence should be addressed to Jie Li; lijieemail2005@163.com

Received 1 September 2019; Accepted 20 February 2020; Published 1 April 2020

Academic Editor: Srinivas Mutalik

Copyright ©2020 Xi Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Minimally modified low-density lipoprotein (mmLDL) is a risk factor for cardiovascular diseases. The current study explored the effect of mmLDL on the endothelin type A (ETA) receptor in mouse mesenteric arteries \textit{in vivo}, as well as the role of autophagy in this process. mmLDL was injected via the caudal vein, and the Class III PI3K autophagic pathway inhibitor 3-methyladenine (3-MA) was injected intraperitoneally. The animals were divided into physiological saline (NS), mmLDL, and mmLDL + 3-MA groups. The dose-effect curve of endothelin-1- (ET-1-) induced mesenteric artery contraction was measured using myography, while ETA receptor mRNA expression was detected using real-time polymerase chain reactions, and the protein levels of the ETA receptor, class III PI3K, Beclin-1, LC3 II/I, p62, NF-\kappa B, and p-NF-\kappa B were observed using Western blot analysis. mmLDL significantly strengthened ET-1-induced contraction (the $E_{\text{max}}$ value increased from 184.87 ± 7.46% in the NS group to 319.91 ± 20.31% in the mmLDL group ($P < 0.001$), and the pEC\textsubscript{50} value increased from 8.05 ± 0.05 to 9.11 ± 0.09 ($P < 0.01$). In addition to upregulating the protein levels of Class III PI3K, Beclin-1, and LC3 II/I, mmLDL significantly increased the mRNA expression and protein level of the ETA receptor and increased the protein level of p-NF-\kappa B. However, these effects were significantly inhibited by 3-MA. mmLDL activates autophagy via the Class III PI3K/Beclin-1 pathway and upregulates the ETA receptor via the downstream NF-\kappa B pathway. Understanding the effect of mmLDL on the ETA receptor and the underlying mechanisms may provide a new idea for the prevention and treatment of cardiovascular diseases.

1. Introduction

Autophagy is an evolutionally conserved metabolic process; as an important survival mechanism, it degrades and turns over organelles and cytoplasmic contents [1]. The autophagy process consists of the formation of bilayer-membrane autophagosomes, the phagocytosis of cytoplasmic substances, and the fusion of autophagosomes with lysosomes for degradation. The formation of autophagosomes depends on the assembly of Beclin-1- and Class III PI3K-containing phospholipid kinase signaling complexes. These complexes mediate the nucleation of the autophagosomal precursor and activate two ubiquitin-like binding pathways (Atg5-Atg12 and microtubule-associated protein light-chain 3-phospholipid conjugates) to promote separation and membrane expansion [2, 3].

The endothelin (ET) system is composed of ligands and receptors, and an imbalance in this system plays an important role in the pathogenesis of cardiovascular diseases. ET-1 serves as a highly active vasoconstrictor that activates the endothelin type A (ET\textsubscript{A}) and endothelin type B (ET\textsubscript{B}) receptors. ET-1 imbalance is associated with pathological...
conditions, such as arteriomesenteric ischemia reperfusion [4]. The ETA receptor is highly expressed on the vascular smooth muscle cells (VSMCs) of the entire cardiovascular system, which mediates the constriction, proliferation, apoptosis, and fibrosis of the vessels [5]. In myocytes with the specific knockout of ETA receptors, aging-induced myocardial hypertrophy and contractile dysfunction are improved, during which autophagy exerts an important role [6].

Minimally modified low-density lipoprotein (mmLDL) is a mildly oxidized low-density (oxLDL) lipoprotein in which some of the lipids are oxidized but that maintains an integral apolipoprotein B structure. mmLDL can be identified by LDL receptors other than macrophage scavenger receptors [7]. mmLDL induces the proinflammatory effect of macrophagocytes, which includes cytoskeletal rearrangement, macrophage pinocytosis, ROS production, foam cell formation, and decreased apoptotic cell phagocytosis [8]. mmLDL possesses multiple atherosclerosis-promoting features. For instance, mmLDL induces the adhesion of monocytes to endothelial cells to generate colony-stimulating factors, monocyte chemotactic protein-1, and tissue factor, which causes damage to endothelial cells and promotes oxLDL generation; additionally, mmLDL can activate multiple apoptotic signaling pathways in human coronary artery cells [9].

Here, for the first time, we explored the effect of mmLDL on arteriomesenteric ETA receptors in vivo and the role of autophagy in this process. The results of this study may deepen the understanding of the vascular biological mechanisms of mmLDL.

2. Materials and Methods

2.1. mmLDL Preparation. The thiobarbituric acid-reactive substance (TBARS) method and agarose gel electrophoresis were used for examining differences between LDL, mmLDL, and oxLDL. According to the TBARS method, the oxidized apolipoprotein B, the cholesterol oxidation products, and the lipid peroxidation products in blood plasma are all able to react with thiobarbituric acids to form malondialdehyde-like structures, and the oxidation degree of LDL can subsequently be assessed based on the number of the structures. The natural concentration of the malondialdehyde-like structures of LDL is lower than 4 μmol/g LDL, whereas the natural concentrations of mmLDL and oxLDL are between 5 μmol/g LDL and 20 μmol/g LDL and beyond 20 μmol/g LDL, respectively. According to agarose gel electrophoresis, oxLDL has the highest level of oxidation with a large number of electrical negatives at a fast migration rate, which is followed by mmLDL and then LDL [10, 11].

Human LDL (0.2 mg/mL; Sigma, St. Louis, MO, USA) was applied to EDTA-free phosphate-buffered saline (PBS) containing 1 μmol/L FeSO₄. After a 96-hour dialysis at 4°C, 0.25 mM EDTA was used to terminate the oxidizing reaction for mmLDL [10, 11]. The mmLDL was concentrated to 1 mg/mL. The degree of mmLDL oxidation was determined with TBARS, and the result showed that the concentration of malondialdehyde-like structures was 10.36 ± 1.15 μmol/g LDL. Electrophoresis (0.8% agarose gel) showed that the mobility of mmLDL was 1.66–1.70 times that of LDL. The prepared mmLDL was stored away from light at 4°C and used within 2 weeks.

2.2. Animals and Grouping. SPF-level ICR mice of both sexes, with age ranging from 8 weeks to 11 weeks and a weight of 20–24 g, were purchased from the animal center of Xi’an Jiaotong University, China. The animals had free access to water and food and were divided for different purposes, with 10 animals in each group. The animal treatment protocols were approved by the Institute of Animal Ethics of Xi’an Jiaotong University.

To investigate the effect of mmLDL on mouse arteriomesenteric ETA receptors, the mmLDL group received 8 injections of 1 mg/kg mmLDL via the caudal vein at an injection interval of 12 h. At 96 h, the animals were killed via cervical dislocation after eyeball blood was drawn; then, the mesenteric arteries were collected for subsequent experiments [11–13]. The normal saline (NS) group and the LDL group were given the same dosage of physiological saline and LDL, respectively.

To explore the effect of the Class III PI3K/Beclin-1 pathway, an intraperitoneal injection of the Class III PI3K inhibitor 3-methyladenine (3-MA; MedChemExpress, Shanghai, China) was simultaneously administered to the animals. To determine the optimal dose of 3-MA, 5, 15, and 25 mg/kg groups were designed. The required concentration of 3-MA was prepared with double distilled water. The injection was performed 2 h before the first injection of mmLDL every day, once per day. At 96 h, the mice were killed using the cervical dislocation method, and 3-MA was not given within 2 h before the sacrifice [12]. The optimal 3-MA dose was determined based on ETA receptor-mediated vasoconstriction curves.

2.3. Detection of Vasoconstriction Function. After a mouse was killed, the tissue containing the mesenteric arteries was immediately collected and then immersed in a Na+-Krebs solution (containing 15 mM NaHCO₃, 119 mM NaCl, 1.2 mM MgCl₂, 1.2 mM NaH₂PO₄, 1.5 mM dehydrated CaCl₂, 4.6 mM KCl 4.6, and 5.5 mM glucose) at 4°C. The surrounding tissue was isolated under a microscope, and a 10 s intrascular perfusion was performed with 0.1% Triton x-100. The vascular endothelium was removed. The sample was washed with buffer for 10 s, and then 20 μM 5-HT was used for a preshrinking test. When the acetylcholine-(ACh-; 10μM) induced diastolic rate was lower than 10%, the endothelium was considered successfully removed.

The arteries were cut into rings with a length of 1-2 mm. Two metal wires with a diameter of 40 μm were inserted through the rings, with one connected to a load tension readjustment equipment and the other connected to a myographer (Danish Myo Technology A/S, DMT, Denmark). The rings were placed into a thermostatic tank (37°C) full of Na+-Krebs solution. To achieve oxygen saturation, mixed gas containing 95% O₂ and 5% CO₂ was continuously ventilated. The pH value was maintained at approximately
7.4, and the resting tension was maintained at 1.5 mN. The Krebs solution was replaced every 20 min, with an equilibrium time of 1.5 h. K⁺-Krebs solution (containing 15 mM NaHCO₃, 1.2 mM NaH₂PO₄, 1.5 mM CaCl₂, 63.5 mM KCl, 1.2 mM MgCl₂, 60 mM NaCl, and 5.5 mM glucose) was applied to detect the activity of the rings. The arterial rings were rinsed three times. The abovementioned procedures were repeated. When the contractile amplitudes caused by the two applications of K⁺-Krebs liquid were both higher than 1 mN and the difference between the contractile amplitudes was within 10%, subsequent experiments were carried out. To investigate ET₄ receptor-mediated contractile function, the vascular rings were incubated with the ET₄ receptor antagonist BQ-788 at 0.1 μM (Sigma, St. Louis, MO, USA) for 30 min. Then, ET-1 (Enzo Biochem, Shanghai, China) (ET-1 is the agonist of the ET₄ and ET₃ receptors, and ET₄ receptor-specific agonists have not been discovered) at 10⁻¹⁻¹⁰⁻² M was added using the concentration accumulation method, and the dose-effect curve of ET₄ receptor-mediated vasoconstriction was obtained [14, 15]. The pretest showed that the simultaneous intraperitoneal injection of polymyxin B during the caudal vein injection of mmLDL did not affect the effect of mmLDL, and therefore, the possibility of endotoxic interference was excluded.

2.4. Real-Time Polymerase Chain Reaction (RT-PCR). Total RNA was extracted using the RNA extraction kit (Proteintech Biotechnology, USA), and the procedures were performed in strict accordance with the kit instructions. The absorbance at 260 nm and 280 nm was detected to determine the concentration and purity of the total RNA. Reverse transcription was performed for cDNA (Perkin-Elmer Applied Biosystems, USA). A fluorescent quantitative PCR instrument (LightCycler 480 II system) was used for RT-PCR. A SYBR Green kit was utilized for gene amplification, and CDNA was used as the template. A control group was established, and the procedures were same as those performed for the experimental group except for the addition of cDNA. The forward and reverse primers of the ET₄ receptor were 5′-TACTCAGC-3′ and 5′-TCAACGGCACAGTCAAG-3′, respectively, and those of the housekeeping gene GAPDH were 5′-TCAACGGCACAGTCAAG-3′ and 5′-ACTTCCACGACA-TACTCAGC-3′, respectively. The reaction system was 25 μL, and the conditions included 95°C for 5 min followed by 40 cycles of 94°C for 20 s, 55°C for 20 s, and 72°C for 30 s. Separation efficiency curves were used for the analysis of the specificity of the PCR products, and the cycle threshold (Ct) method was used for quantitative mRNA analysis. The Ct value of GAPDH was used as the internal reference, and the relative mRNA expression of the ET₄ receptor was calculated based on that value.

2.5. Western Blotting Analysis. Each sample consisted of two mesenteric arteries from the same group. RIPA lysis buffer containing protease inhibitors was added, and homogenate was prepared. A BCA kit was used for protein quantification. The extracted protein was subjected to SDS-PAGE followed by isolation and PVDF membrane transfer. Evaporated milk (5%; prepared with T-TBS buffer) was applied for sample blocking. The primary antibodies included ET₄ receptor antibody (dilution, 1:500; GeneTex, Inc., USA), Class II PI3K antibody (1:1000; Cell Signaling Technology), p-NF-κB p65 antibody (1:1000; Cell Signaling Technology), Beclin-1 antibody (1:3000; Proteintech Biotechnology, Inc., USA), LC3 antibody (1:500; Proteintech Biotechnology), p62 antibody (1:3000; Proteintech Biotechnology), NF-κB antibody (1:3000; Proteintech Biotechnology), and GAPDH antibody (1:1000; Proteintech Biotechnology), and they were prepared with PBS containing 2% bovine serum albumin as the diluent. The secondary antibodies were peroxidase-labeled goat anti-rabbit IgG and goat anti-mouse IgG (both, 1:5000). Images were taken with Image Gauge Ver. 4.0 (Fuji Photo Film Co., Ltd, Japan) for optical density analysis. Grayscale self-correction was performed. The level of the target protein is presented as the ratio between the band grayscale of the target gene and that of the housekeeping gene.

2.6. Serum oxLDL Determination. After the animals were sacrificed, the eyeballs were excised, and blood was collected. The blood sample was coagulated at room temperature for 30 min. The sample was centrifuged at 845 ×g for 30 min at 4°C, and the supernatant was collected for analysis. The concentration of serum oxLDL was determined using enzyme-linked immunosorbent assays (ELISAs). The procedures were performed in strict accordance with the kit instructions (Dakewe Biotech Company Limited, Shenzhen, China). Standard curves were generated based on the oxLDL content in the sample.

2.7. Statistical Analysis. Data are presented as the mean ± SEM. The contractile response of the vascular ring was presented as the percentage relative to the constriction caused by 63.5 mM of K⁺, and the response characteristics were described with the maximum constriction percentage (E₉₀) and the negative logarithm of the concentration of the receptor agonist causing half E₉₀ (pEC₉₀). Statistical analysis and plotting were performed with Prism 8.0 software. Unpaired Student’s t-test with Welch’s correction was applied to compare two sets of data. One-way analysis of variance (ANOVA) with Dunnett’s posttest was used for multiple comparisons. Two-way ANOVA with Bonferroni’s posttest was performed to compare the two corresponding data points at each concentration of the two curves. P < 0.05 was considered statistically significant.

3. Results

3.1. The Contractile Response of the Vascular Rings, the Effect of Arterial Endothelium Removal, and the Level of oxLDL. The constriction values of the vascular rings in response to 63.5 mM K⁺ did not show significant differences among the groups (mmLDL, 2.89 ± 0.47 mN; mmLDL + 3-MA, 2.78 ± 0.38 mN; NS, 2.90 ± 0.42 mN; LDLr, 2.86 ± 0.44 mN; P > 0.05, n = 8). Each vascular ring was preconstricted with
20 μM 5-HT followed by dilatation with 10 μM ACh, and the dilatation value was lower than 5% of the preconstriction value, indicating the complete removal of the endothelium. The serum αxLDL concentrations showed a slight difference between the NS group and the mmLDL group, although no significant difference was observed (112.58 ± 6.38 μg/L vs. 111.32 ± 5.84 μg/L; P > 0.05, n = 8).

3.2. Inhibitory Effect of 3-MA on the mmLDL-Induced Upregulated Expression of the ETA Receptor. Compared with the NS group, the mmLDL group showed noticeably increased ETA receptor-mediated vasoconstriction, with a noticeable leftward shift of the dose-effect curve. The E\text{max} value increased from 201.58 ± 16.63% in the NS group to 346.16 ± 29.46% in the mmLDL group (P < 0.001), and the pEC_{50} value increased from 8.05 ± 0.05 in the NS group to 9.11 ± 0.09 in the mmLDL group (P < 0.01) (Figure 1(a)). mmLDL increased the levels of the ETA receptor: the mRNA expression of the ETA receptor increased from 1.06 ± 0.05 (NS) to 2.12 ± 0.09 (P < 0.001), and the protein level of the ETA receptor increased from 0.14 ± 0.01 (NS) to 3.32 ± 0.01 (mmLDL) (P < 0.001) (Figures 1(b) and 1(c)). The supporting data are shown in Supplementary File 1.

To explore the effect of 3-MA on the experimental outcomes, as well as its optimal dose, the animals were divided into three groups for 3-MA intraperitoneal injections (5, 15, and 25 mg/kg). 3-MA inhibited the mmLDL-induced improvements in vasoconstriction in a dose-dependent manner. Compared with the mmLDL group, the 5 mg/kg group showed a slightly rightward shift of the vasoconstriction curve, with a slightly decreased E\text{max} value (346.16 ± 29.46% vs. 316.59 ± 33.63%; P > 0.05) and a slightly decreased pEC_{50} value (9.11 ± 0.09 vs. 8.82 ± 0.09; P > 0.05). Compared with the mmLDL group, the 15 mg/kg group exhibited a noticeable rightward shift of the constriction curve (E\text{max}: 346.16 ± 29.46% vs. 242.85 ± 27.25%, P < 0.001; pEC_{50}: 9.11 ± 0.09 vs. 8.22 ± 0.09, P < 0.005). Although the constriction curve of the 25 mg/kg group showed a slightly rightward shift compared with that of the 15 mg/kg group, no significant differences were observed (in the 25 mg/kg group, the E\text{max} and pEC_{50} values were 224.07 ± 24.23% and 8.05 ± 0.06, respectively; Figure 1(a)). Therefore, 15 mg/kg was used as the optimal dose of 3-MA to further explore the role of Class III PI3K/Beclin-1 in the upregulation of the ETA receptor induced by mmLDL. 3-MA at 15 mg/kg significantly inhibited the strengthening effect of mmLDL on the ETA receptor: the mRNA expression and protein level of the ETA receptor decreased to 1.28 ± 0.06 (P < 0.001) and 0.21 ± 0.01 (P < 0.001) (Figures 1(b) and 1(c)). The caudal vein injection of LDL at 1 mg/kg did not markedly affect the ETA receptor-mediated constriction curve (Figure 1(a)).

3.3. Inhibitory Effect of 3-MA on the mmLDL-Induced Effects on Class III PI3K, Beclin-1, LC3 II/I, and p62 Proteins. After caudal vein injection of mmLDL, the protein levels of Class III PI3K, Beclin-1, and LC3 II/I increased from 0.75 ± 0.04, 1.79 ± 0.24, and 0.80 ± 0.04 to 1.17 ± 0.04, 4.01 ± 0.17, and 1.33 ± 0.05 (P < 0.001, P < 0.001, and P < 0.001), respectively, and the p62 protein level decreased from 3.35 ± 0.10 (NS) to 1.23 ± 0.09 (P < 0.001). 3-MA significantly decreased the mmLDL-induced increase in the protein levels of Class III PI3K, Beclin-1, and LC3 II/I to 0.84 ± 0.05, 2.36 ± 0.34, and 0.66 ± 0.03 (P < 0.001, P < 0.01, and P < 0.001), respectively, and increased the mmLDL-induced decrease in p62 protein level to 2.44 ± 0.13 (P < 0.001), indicating that 3-MA inhibited the autophagy activation caused by mmLDL (Figures 2(a)–2(d); Supplementary File 2).

3.4. Inhibitory Effect of 3-MA on the mmLDL-Induced Effect on p-NF-κB Protein. The mmLDL group showed an increased level of arteriomesenteric p-NF-κB protein, which increased from 0.14 ± 0.01 (NS) to 0.41 ± 0.02 (P < 0.001). Compared with the mmLDL group, the 3-MA group showed a significantly decreased p-NF-κB level (0.17 ± 0.01; P < 0.001; Figure 3(a)). The NF-κB protein levels in the NS, mmLDL, and 3-MA+mmLDL groups were 0.15 ± 0.04, 1.16 ± 0.01, and 0.14 ± 0.01, respectively (all P > 0.05; Figure 3(b)). The supporting data for this analysis are shown in Supplementary File 3.

4. Discussion

mmLDL is a risk factor for cardiovascular diseases, which causes damage to endothelial cells and induces the production of foam cells. However, the pathogenic mechanisms of mmLDL remain unclear. For the first time, this study indicated that caudal vein injection of mmLDL could upregulate the ETA receptor level in mouse arteriomesenteric smooth cells to strengthen ETA receptor-mediated vasoconstriction. Furthermore, this study discovered that the Class III PI3K/Beclin-1 autophagy pathway participated in the regulation of the arteriomesenteric ETA receptor level in mice in vivo for the first time.

The increased ETA receptor level plays an important role in the pathogenesis of multiple cardiovascular diseases, such as hypertension [16, 17], pulmonary hypertension [18, 19], dilated cardiomyopathy, and microvascular dysfunction [20, 21]. ETA receptor knockout can reverse or reduce the aging-induced downregulation of autophagy markers [6]. In the myocardial cell protection mediated by ETA receptor knockout or the application of ETA receptor antagonists, autophagy plays a critical role [22]. 3-MA eliminates the effect on cardiovascular proteins induced by the ETA receptor antagonist BQ123 and inhibits the formation of autophagosomes and the degradation of lysosomes; however, both of these effects can be reversed by ETA receptor knockdown [6]. In this study, 3-MA inhibited the mmLDL-induced upregulation of the ETA receptor, which also indicated the important roles of autophagy in the regulation and protection of the cardiovascular system.

Autophagy is closely associated with cardiovascular diseases: physiological conditions, such as nutritional deficiency, can induce the autophagy of isolated myocardial
Figure 1: 3-MA inhibits the effect of mmLDL on the ET\textsubscript{A} receptor in VSMCs. (a) 3-MA antagonizes the mmLDL-strengthened contractile curves induced by ET-1 in a dose-dependent manner. (b) The mRNA expression of the ET\textsubscript{A} receptor (relative to GAPDH; \(n=6\)). (c) The protein levels of the ET\textsubscript{A} receptor (\(n=4\), with each sample as a pool of 2 mesenteric arteries). Data are presented as the mean ± SEM. Statistical analyses were performed using one-way analysis of variance (ANOVA) with Dunnett’s posttest and two-way ANOVA with Bonferroni’s posttest. *** \(P<0.001\) vs. the NS (normal saline) group. ## \(P<0.01\) and ### \(P<0.001\) vs. the mmLDL group.
cells, vascular epithelial cells, and VSMCs [23]. Under these conditions, autophagy can improve the accumulation and degradation of organelles and proteins that are lower than normal levels [24]. Under cardiovascular stress, such as ischemia reperfusion and heart failure, autophagy can be activated. However, whether autophagy is beneficial or harmful under these conditions of stress has not been definitively determined [25, 26].
VSMC autophagy has an important role in vascular disease development [27]. During autophagy, microvessel-associated LC3-I transforms from the cytoplasmic form to the LC3 phosphatidylethanolamine-binding form (LC3-II) to promote the formation of autophagosomes, thereby maintaining their growth. The formation of LC3-II is normally used as an indicator of autophagy activation [28]. In this study, LC3-II showed a relatively high protein level in VSMCs after mmLDL injection, which indicated that mmLDL increased the autophagy level of VSMCs. In contrast, 3-MA inhibited the effect of mmLDL on autophagy activation and downregulated the protein ratio of LC3-II/LC3-I, which indicated that 3-MA reduced the autophagy level of VSMCs.

p62 (a scaffold protein) and LC3-II interact with poly-ubiquitated proteins, which causes the degradation of the latter. The activation of the autophagy process can decrease the content of p62. Therefore, the p62 level can indicate whether autophagy is complete [29]. In this study, compared with NS, mmLDL significantly decreased the p62 level in VSMCs in vivo, which indicated that mmLDL activated the autophagy process.

Beclin-1 is associated with the formation of autophagic vacuoles, and its level has been considered to be a reliable marker to detect autophagy flux [30]. In this study, compared with NS, mmLDL upregulated the protein levels of Beclin-1 and Class III PI3K, which indicated that mmLDL promoted the formation of the autophagic vacuoles in VSMCs. mmLDL not only increased the ETA receptor level in VSMCs but also induced the autophagy of VSMCs.

The NF-κB pathway participates in the upregulation of the ET_A receptor in VSMCs in vitro [31]. As a stress-sensitive transcription factor, NF-κB possesses remarkable proliferation and anti-apoptotic and pro-inflammatory effects. The activation of NF-κB upregulates Beclin-1 and promotes autophagy [32]. Beclin-1/Atg6 and Class III PI3K/Vps34 act jointly, recruiting autophagy activators and inhibitors to adjust the formation of autophagosomes in a specific manner [33]. LC3 binds to phosphatidylethanolamine, which allows it to integrate with the membrane of autophagosomes for autophagosome formation [34]. In this study, mmLDL upregulated the protein phosphorylation level of NF-κB, whereas 3-MA downregulated the mmLDL-induced increase in NF-κB phosphorylation, which indicated that Class III PI3K/Beclin-1 participated in NF-κB activation. For the first time, this study elucidated that the NF-κB pathway participated in the mmLDL-induced upregulation of the ET_A receptor in VSMCs.

mmLDL upregulates the protein levels of Class III PI3K, Beclin-1, and LC3 II/I in arteriomesenteric VSMCs and downregulates the protein level of p62; that is, mmLDL activates the autophagy of VSMCs and upregulates the protein and mRNA expression of the ET_A receptor to strengthen the ET_A receptor-mediated vasoconstriction effect. In addition, the autophagy activation of VSMCs affects the upregulation of the ET_A receptor. 3-MA downregulates the increased autophagy level induced by mmLDL and inhibits the upregulation of the ET_A receptor caused by mmLDL. Therefore, mmLDL activates the autophagy of arteriomesenteric VSMCs in vivo to upregulate the ET_A receptor level.

Data Availability
The data used to support the findings of this study are included within the article and the supplementary files.

Conflicts of Interest
The authors declare no conflicts of interest.

Authors’ Contributions
Xi Xie and Chen Chen contributed equally to this work.

Acknowledgments
This study was financially supported by the National Natural Science Foundation of China (Nos. 81202535 and 81470493), the Hunan Provincial Department of Education (Nos. 19K084 and 19C1722), the Hunan Provincial Science and Technology Department (2018J6097), the Science and Technology Bureau of Chenzhou, Hunan Province, (zdy201821 and zdy201925), and the Research Center of Diagnosis and Treatment Technology for Lipid Metabolism Disorders of Chenzhou, Hunan Province (yfzx201907).

Supplementary Materials
Supplementary File 1: inhibitory effect of 3-MA on the mmLDL-induced upregulated expression of the ETA receptor. Supplementary File 2: inhibitory effect of 3-MA on the mmLDL-induced effects on Class III PI3K, Beclin-1, LC3 II/I, and p62 proteins. Supplementary File 3: inhibitory effect of 3-MA on the mmLDL-induced effect on p-NF-κB protein.

References
[1] S. Lavandero, R. Roncoso, B. A. Rothermel, W. Martinet, J. Sadoshima, and J. A. Hill, "Cardiovascular autophagy: concepts, controversies, and perspectives," Autophagy, vol. 9, no. 10, pp. 1455–1466, 2013.
[2] D. Gatica, M. Chiong, S. Lavandero, and D. J. Klionsky, "Molecular mechanisms of autophagy in the cardiovascular system," Circulation Research, vol. 116, no. 3, pp. 456–467, 2015.
[3] Y. Feng, D. He, Z. Yao, and D. J. Klionsky, "The machinery of macroautophagy," Cell Research, vol. 24, no. 1, pp. 24–41, 2014.
[4] S. Martinez-Revelles, L. Caracuel, A. Márquez-Martín et al., "Increased endothelin-1 vasoconstriction in mesenteric resistance arteries after superior mesenteric ischaemia-reperfusion," British Journal of Pharmacology, vol. 165, no. 4, pp. 937–950, 2012.
[5] A. P. Davenport and J. J. Maguire, "Endothelin," Handbook of Experimental Pharmacology, vol. 118, no. 176 Pt 1, pp. 295–329, 2006.
[6] A. F. Ceylan-Isik, M. Dong, Y. Zhang et al., "Cardiomyocyte-specific deletion of endothelin receptor a rescues aging-associated cardiac hypertrophy and contractile dysfunction:
role of autophagy,” Basic Research in Cardiology, vol. 108, no. 2, p. 335, 2013.

[7] S. J. Ann, K. K. Kim, E. J. Cheon et al., “Palmitate and minimally-modified low-density lipoprotein cooperatively promote inflammatory responses in macrophages,” PloS One, vol. 13, no. 3, Article ID e0193649, 2018.

[8] S.-H. Choi, D. Sviridov, and Y. I. Miller, “Oxidized cholesteryl esters and inflammation,” Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1862, no. 4, pp. 393–397, 2017.

[9] Y. I. Miller, S. Viriyakosol, C. J. Binder, J. R. Feramisco, T. N. Kirkland, and J. L. Witzym, “Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 1561–1568, 2003.

[10] H. Itabe, M. Mori, Y. Fujimoto, Y. Higashi, and T. Takano, “Minimally modified LDL is an oxidized LDL enriched with oxidized phosphatidylcholines,” Journal of Biochemistry, vol. 134, no. 3, pp. 459–465, 2003.

[11] J.-J. Wang, X.-L. Chen, C.-B. Xu et al., “The ERK1/2 pathway participates in the upregulation of the expression of mesenteric artery α1 receptors by intravenous tail injections of mmLDL in mice,” Vascular Pharmacology, vol. 77, pp. 80–88, 2016.

[12] Y. Liu, X.-L. Chen, C.-B. Xu et al., “Tail vein injection of mmLDL upregulates mouse mesenteric artery ET B receptors via activation of the ERK1/2 pathway,” Vascular Pharmacology, vol. 96–98, pp. 33–39, 2017.

[13] G. Chen, J. J. Wang, C. B. Xu et al., “Minimally modified LDL-induced impairment of endothelium-dependent relaxation in small mesenteric arteries of mice,” Journal of Vascular Research, vol. 53, no. 1-2, pp. 58–71, 2016.

[14] J. Li, L. Cao, C. B. Xu, J. J. Wang, and Y. X. Cao, “Minimally modified LDL upregulates endothelin type A receptors in rat coronary arterial smooth muscle cells,” Mediators of Inflammation, vol. 2013, Article ID 656570, 11 pages, 2013.

[15] H. Ahnstedt, M. Mostajeran, F. W. Blixt et al., “U0126 attenuates cerebral vasconstriction and improves long-term neurologic outcome after stroke in female rats,” Journal of Cerebral Blood Flow & Metabolism, vol. 35, no. 3, pp. 454–460, 2015.

[16] S. A. Nasser, A. I. Elmallah, R. Sabra, M. M. Khedr, M. M. M. El-Din, and M. M. El-Mas, “Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions,” European Journal of Pharmacology, vol. 727, pp. 52–59, 2014.

[17] M. M. El-Mas, M. M. Mohy El-Din, M. M. Helmy, and A. G. Omar, “Redox imbalances incite the hypertensive, baroreflex, and autonomic effects of cyclosporine in rats,” European Journal of Pharmacology, vol. 694, no. 1-3, pp. 82–88, 2012.

[18] I. S. Hong, H. V. Coe, and L. M. Catanzaro, “Macitentan for the treatment of pulmonary arterial hypertension,” Annals of Pharmacotherapy, vol. 48, no. 4, pp. 538–547, 2014.

[19] K. Taguchi and Y. Hattori, “Unlooked-for significance of cardiac versus vascular effects of endothelin-1 in the pathophysiology of pulmonary arterial hypertension,” Circulation Research, vol. 112, no. 2, pp. 227–229, 2013.

[20] D. E. Kohan and D. M. Pollock, “Endothelin antagonists for diabetic and non-diabetic chronic kidney disease,” British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 573–579, 2013.

[21] L. Holzhauser and R. Zolty, “Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening,” Heart Failure Reviews, vol. 19, no. 6, pp. 743–758, 2014.

[22] R. M. Redzierski, P. A. Grayburn, Y. Y. Kisanuki et al., “Cardiomycocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol,” Molecular and Cellular Biology, vol. 23, no. 22, pp. 8226–8232, 2003.

[23] J. K. Salabei and B. G. Hill, “Implications of autophagy for vascular smooth muscle cell function and plasticity,” Free Radical Biology and Medicine, vol. 65, pp. 693–703, 2013.

[24] A. Nemchenko, M. Chiong, A. Turer, S. Lavander, and J. A. Hill, “Autophagy as a therapeutic target in cardiovascular disease,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 584–593, 2011.

[25] O. F. Rifki and J. A. Hill, “Cardiac autophagy,” Journal of Cardiovascular Pharmacology, vol. 60, no. 3, pp. 248–252, 2012.

[26] Z. V. Wang, A. Ferdous, and J. A. Hill, “Cardiomycocyte autophagy: metabolic profit and loss,” Heart Failure Reviews, vol. 18, no. 5, pp. 585–594, 2013.

[27] M. O. Grootaert, P. A. da Costa Martins, N. Bitsch et al., “Defective autophagy in vascular smooth muscle cells accelerates senescence and promotes neointima formation and atherogenesis,” Autophagy, vol. 11, no. 11, pp. 2014–2032, 2015.

[28] H. He, Y. Dang, F. Dai et al., “Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B,” Journal of Biological Chemistry, vol. 278, no. 31, pp. 29278–29287, 2003.

[29] M. Komatsu, S. Waguri, M. Koike et al., “Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice,” Cell, vol. 131, no. 6, pp. 1149–1163, 2007.

[30] Z. Yue, S. Jin, C. Yang, A. J. Levine, and N. Heintz, “Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor,” Proceedings of the National Academy of Sciences, vol. 100, no. 25, pp. 15077–15082, 2003.

[31] J. Li, Y.-X. Cao, Y. Liu, and C.-B. Xu, “Minimally modified LDL upregulates endothelin type B receptors in rat basilar artery,” Microvascular Research, vol. 83, no. 2, pp. 178–184, 2012.

[32] T. Copetti, C. Bertoli, E. Dalla, F. Demarchi, and C. Schneider, “p65/RelA modulates BECN1 transcription and autophagy,” Molecular and Cellular Biology, vol. 29, no. 10, pp. 2594–2608, 2009.

[33] S. Pattingre, L. Espernt, M. Biard-Piechaczyk, and P. Codogno, “p65/RelA regulates a novel type of modification for MAP1LC3B,” Journal of Biological Chemistry, vol. 279, no. 4, pp. 393–397, 2013.